uniQure's AMT-130 Gene Therapy Under FDA Review, Shares Surge 10.84%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Benzinga
- FDA Review Progress: uniQure announced that the FDA will review the data package for its Huntington's disease gene therapy AMT-130, with a Type A meeting scheduled, indicating positive regulatory progress that could expedite the approval process.
- CEO Outlook: CEO Matt Kapusta highlighted the urgent need for treatments that can slow or alter the course of Huntington's disease, underscoring the therapy's market demand and societal value.
- Stock Price Reaction: Following the announcement, uniQure's stock surged 10.84% to $25.66 per share, reflecting investor optimism about the company's future prospects, which may attract more investor interest.
- Future Plans: uniQure plans to share regulatory updates after receiving the official meeting minutes, further enhancing market confidence in its product and potentially driving continued stock price appreciation.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QURE is 49.88 USD with a low forecast of 33.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 23.020
Low
33.00
Averages
49.88
High
70.00
Current: 23.020
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of QURE's 52-Week High and Low Points
- Price Range Analysis: QURE's 52-week low is $7.76 per share, while the high is $71.50, with the last trade at $23.88, indicating significant volatility in its stock price over the past year, reflecting varying market expectations for its future performance.
- Technical Indicator Focus: The current stock price is below the 200-day moving average, which may suggest increased selling pressure in the short term, prompting investors to monitor subsequent trends to assess potential investment risks.
- Market Sentiment Insight: Although the current stock price is significantly lower than the 52-week high, it remains above the low, indicating that the market still holds some confidence in QURE's fundamentals, potentially attracting investors looking for entry points at lower prices.
- Investor Strategy Adjustment: Investors should consider QURE's price volatility and technical indicators, along with market sentiment, to adjust their strategies in response to potential market changes.
Continue Reading
uniQure (QURE) Stock Plummets 50% After FDA Rejects BLA Submission for AMT-130
- FDA Notification Impact: On November 3, 2025, uniQure disclosed that the FDA indicated its clinical data for AMT-130, a gene therapy for Huntington's disease, was insufficient to support the Biologics License Application (BLA), leading to significant regulatory challenges for the company.
- Stock Price Volatility: Following this announcement, uniQure's stock plummeted over 50%, from $67.69 on October 31, 2025, to $34.29, reflecting extreme market pessimism regarding the company's future prospects.
- Investor Scrutiny: Kessler Topaz Meltzer & Check LLP is investigating potential violations of federal securities laws by uniQure, indicating heightened investor concerns about the company's compliance and transparency.
- Future Uncertainty: uniQure stated that the timing for the BLA submission for AMT-130 is now unclear, which could impact the company's fundraising and R&D efforts, posing a threat to its long-term strategic objectives.
Continue Reading